Petvivo Holdings Inc

Greetings everyone and welcome to the Pet Vivo Holdings first quarter of fiscal 2023 financial results conference call. I am John Dolan, the Chief Business Development Officer and General Counsel at Pet Vivo. Today's call is being webcast and will be posted on the company's website for playback. Before we begin, I would like to remind everyone that comments made during this conference call by Pet Vivo executives may contain forward-looking statements within the meaning of the private Securities Litigation and Reform Act of 1995, and are subject to risks and uncertainties. Any statement that refers to expectations, projections, or other characterizations of future events, including financial projections or future market conditions, is a forward-looking statement. PADVivo's actual future results could differ materially from those expressed in such forward-looking statements for any reason, including those listed in its SEC filings. Pet Vivo assumes no obligation to update any such forward-looking statements. Pet Vivo filed its earnings release and form 10Q with the SEC today, which provides a detailed discussion of our financial results. These documents can be found in the SEC website and the investor relations section of our website. I would like to turn the conference over to John Lai, the CEO and President of Pet Vivo. Please go ahead, John.

Thank you, John, and welcome. Joining me today is Robert Foulkes, our Chief Financial Officer. I would like to begin discussing some highlights for the last quarter. Then Bob Foulkes will discuss our financial results and financial condition in greater detail. I will continue by sharing some of the additional thoughts from our business strategy as well as key focus areas for fiscal 2023 before we open the lineup for questions. Our key highlights for the first quarter of fiscal 2023 were we entered into a exclusive distribution and sales agreement with MWI subsidiary of AmerisourceBergen, ticker symbol ABC, which is a leading distributor of animal health products. We also have accounts now in 37 states. So that's pretty, we're getting good coverage in the MAP area. I would like to turn the call over to Robert Foulkes, our Chief Financial Officer, who had discussed recently completed register offering and our financial condition.

Robert Foulkes, Chief Financial Officer, Oh, thank you, John. And good afternoon, everyone. At June 30th, 2022, the company had 4.4 million in cash and working capital of 3.8 million. We increased our inventory to 181,000. in order to support our expected revenue growth in 2023, fiscal 23. And as John mentioned, we've opened our awareness of sales and marketing, our investment in sales and marketing has been paying off with opening these accounts. And we continue to use the net proceeds from our initial public offering to expand our sales and marketing efforts and also clinical studies to gain Fed acceptance and increase our revenues from the sale of spring. And so now I will turn the call back to John.